Castle Biosciences announces publication of new SRMA on TissueCypher

Castle Biosciences (CSTL) announced the publication of a new systematic review and meta-analysis, SRMA, demonstrating that the TissueCypher Barrett’s Esophagus test provides clinically validated risk stratification for patients with Barrett’s esophagus, BE. The findings confirm that TissueCypher can outperform traditional pathology or clinical factors alone to identify patients at increased risk of developing esophageal cancer. The paper, titled “The Tissue Systems Pathology Test Predicts Risk of Progression in Patients With Barrett’s Esophagus: Systematic Review and Meta-Analysis,” was published in the Journal of Clinical Gastroenterology. Key findings of the SRMA indicate TissueCypher can help physicians: Identify patients at highest risk: Across six published studies, patients with high-risk TissueCypher results were 6.7 times more likely to progress to HGD or EAC within five years than those with low-risk results. Guide care with confidence: Patients with high or intermediate-risk results had an annual progression rate of 2.8%, and those with high-risk results had a rate of 5.6% per year, both above the 1.7% annual progression rate typically reported for patients with LGD, a clinical benchmark for therapeutic intervention